Evidence map›Paper›PMID 27815832›Full record

SynthesisMolecular neurobiology2017

Peripheral Brain-Derived Neurotrophic Factor Levels in Alzheimer's Disease and Mild Cognitive Impairment: a Comprehensive Systematic Review and Meta-analysis.

Bo Yi Kim, Seon Heui Lee, Petra L Graham, Francesco Angelucci, Alejandro Lucia, Helios Pareja-Galeano, Thomas Leyhe, Yuda Turana, I Re Lee, Ji Hye Yoon and 1 more

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Molecular neurobiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Non-Genetic Risk Factors of Alzheimer's Disease: An Updated Umbrella Review.The journal of prevention of Alzheimer's disease · 2024
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Plasma BDNF levels in children with ADHD before and after methylphenidate treatment.Scandinavian journal of child and adolescent psychiatry and psychology · 2026
    Article
  9. Article
  10. International journal of molecular sciences · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bo Yi KimCollege of Medicine, Ewha Womans University, Seoul, South Korea.
Seon Heui LeeDepartment of Nursing Science, College of Nursing, Gachon University, Incheon, South Korea.
Petra L GrahamDepartment of Statistics, Macquarie University, Sydney, Australia.
Francesco AngelucciDepartment of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy.
Alejandro LuciaResearch Institute of Hospital 12 de Octubre (i+12), European University of Madrid, Madrid, Spain.
Helios Pareja-GaleanoResearch Institute of Hospital 12 de Octubre (i+12), European University of Madrid, Madrid, Spain.
Thomas LeyheCenter of Old Age Psychiatry, Psychiatric University Hospital, Basel, Switzerland.
Yuda TuranaDepartment of Neurology, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
I Re LeeDepartment of Pediatrics, Yonsei University College of Medicine, 50 Yonsei-Ro, Seoul, 120-752, Republic of Korea.
Ji Hye YoonCollege of Medicine, Ewha Womans University, Seoul, South Korea.
Jae Il ShinDepartment of Pediatrics, Yonsei University College of Medicine, 50 Yonsei-Ro, Seoul, 120-752, Republic of Korea. shinji@yuhs.ac.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is becoming a growing global problem, and there is an urgent need to identify reliable blood biomarkers of the risk and progression of this condition. A potential candidate is the brain-derived neurotrophic factor (BDNF), which modulates major trophic effects in the brain. However, findings are apparently inconsistent regarding peripheral blood BDNF levels in AD patients vs. healthy people. We thus performed a systematic review and meta-analysis of the studies that have examined peripheral BDNF levels in patients with AD or mild cognitive impairment (MCI) and healthy controls. We searched articles through PubMed, EMBASE, and hand searching. Over a total pool of 2061 potential articles, 26 met all inclusion criteria (including a total of 1584 AD patients, 556 MCI patients, and 1294 controls). A meta-analysis of BDNF levels between early AD and controls showed statistically significantly higher levels (SMD [95 % CI]: 0.72 [0.31, 1.13]) with no heterogeneity. AD patients with a low (<20) mini-mental state examination (MMSE) score had lower peripheral BDNF levels compared with controls (SMD [95 % CI]: -0.33 [-0.60, -0.05]). However, we found no statistically significant difference in blood (serum/plasma) BDNF levels between all AD patients and controls (standard mean difference, SMD [95 % CI]: -0.16 [-0.4, 0.07]), and there was heterogeneity among studies (P < 0.0001, I

Indexed as

Alzheimer DiseaseBiomarkersBrain-Derived Neurotrophic FactorCognitive DysfunctionHumansBDNF protein, humanBiomarkersBrain-Derived Neurotrophic FactorAlzheimer’s diseaseBDNFBiomarkersMild cognitive impairment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.